But in 2022, when two students burst into his office and dragged him to a microscope to show him the cluster of cells ... You might recall images of embryonic development from your high-school biology ...

The team led by Robbie Loewith, full professor in the Department of Molecular and Cellular Biology at the UNIGE Faculty of Science ... which can then be observed under an electron microscope. The ...

A heart cockle shell has been found to let in light through a design that resembles fiber optic cables. This could inspire ...

SOLASCURE Ltd ("SolasCure"), a biotechnology company developing a novel treatment to transform chronic wound care and the U.S. Army Institute of Surgical Research ("USAISR"), today announced a ...

With support from a $200,000 instrumentation grant from the North Carolina Biotechnology Center in 2016 ... Thomas Kash, Ph.D. Andrew Hardaway, Ph.D. According to Kash, access to the light sheet ...

With Donald Trump now poised to become U.S. president for the second time in January, biotech and pharmaceutical leaders are preparing for the shift to an administration with a complicated history.

I had to find the right field of view where the differentiated and non-differentiated cells interacted.This took about three hours of precise observation under the microscope to capture the right ...

The first couple of years in retirement are often the most difficult. But they also can set the stage for how you’ll fill the years ahead—both financially and psychologically. Stephen Kreider ...

In Nijmegen, Netherlands, researchers have installed the world's first microscope capable of live imaging of biological processes in such detail that moving protein complexes are visible.

Archon Biosciences came about as most startups do, the result of happenstance and good timing. Unlike many, the biotechnology company also had a Nobel Prize winner to help it along. In 2019, James ...

Shutterstock Monte Rosa Therapeutics signed a development and commercialization deal with Novartis that could pay the biotech up to $2.1 billion. The agreement is for Monte Rosa's MRT-6160 drug ...

Kivu Biosciences, a San Francisco-based biotechnology startup developing targeted drugs for cancer, has raised $92 million in a Series A round, the company said Monday. Kivu will use the funds to ...